Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2007

QGC Forms Partnership with French Organizations Related to Drug Development for Cardiovascular Diseases

  • Quantum Genomics (QGC), Inserm, CNRS, and the University Paris Descartes are collaborating to develop drugs for hypertension and related cardiovascular diseases.

    The first compound, QGC001, to be pursued will be a candidate from discoveries by teams led by Catherine Llorens-Cortes, director of Inserm Unit 691, and Bernard P. Roques at Inserm Unit 640, based in the University of Paris Descartes. QGC expects to start a clinical trial in 2008.

    Under the terms of the contract, QGC acquires rights to exploit three patents and associated know-how. Inserm and CNRS will work on the physiopathology, chemistry, and understanding of the compound's mechanism of action, whereas QGC will handle preclinical and clinical development and regulatory aspects.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »